101. Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
- Author
-
Wong JC, Tang G, Wu X, Liang C, Zhang Z, Guo L, Peng Z, Zhang W, Lin X, Wang Z, Mei J, Chen J, Pan S, Zhang N, Liu Y, Zhou M, Feng L, Zhao W, Li S, Zhang C, Zhang M, Rong Y, Jin TG, Zhang X, Ren S, Ji Y, Zhao R, She J, Ren Y, Xu C, Chen D, Cai J, Shan S, Pan D, Ning Z, Lu X, Chen T, He Y, and Chen L
- Subjects
- Anilides chemistry, Anilides pharmacology, Animals, Biomarkers, Pharmacological metabolism, Carcinoma, Hepatocellular metabolism, Carcinoma, Hepatocellular pathology, Cell Line, Tumor, CpG Islands, Drug Screening Assays, Antitumor, Histone Deacetylase 1 antagonists & inhibitors, Histone Deacetylase Inhibitors pharmacokinetics, Histone Deacetylase Inhibitors pharmacology, Humans, Liver Neoplasms metabolism, Liver Neoplasms pathology, Methylation, Mice, Microsomes, Liver metabolism, Models, Molecular, Molecular Conformation, Morpholines chemistry, Morpholines pharmacology, Neoplasm Transplantation, Pilot Projects, Pyrrolidines chemistry, Pyrrolidines pharmacology, Stereoisomerism, Structure-Activity Relationship, Transcriptome, Transplantation, Heterologous, Anilides chemical synthesis, Carcinoma, Hepatocellular drug therapy, Histone Deacetylase Inhibitors chemical synthesis, Liver Neoplasms drug therapy, Morpholines chemical synthesis, Pyrrolidines chemical synthesis
- Abstract
Herein, we describe the pharmacokinetic optimization of a series of class-selective histone deacetylase (HDAC) inhibitors and the subsequent identification of candidate predictive biomarkers of hepatocellular carcinoma (HCC) tumor response for our clinical lead using patient-derived HCC tumor xenograft models. Through a combination of conformational constraint and scaffold hopping, we lowered the in vivo clearance (CL) and significantly improved the bioavailability (F) and exposure (AUC) of our HDAC inhibitors while maintaining selectivity toward the class I HDAC family with particular potency against HDAC1, resulting in clinical lead 5 (HDAC1 IC₅₀ = 60 nM, mouse CL = 39 mL/min/kg, mouse F = 100%, mouse AUC after single oral dose at 10 mg/kg = 6316 h·ng/mL). We then evaluated 5 in a biomarker discovery pilot study using patient-derived tumor xenograft models, wherein two out of the three models responded to treatment. By comparing tumor response status to compound tumor exposure, induction of acetylated histone H3, candidate gene expression changes, and promoter DNA methylation status from all three models at various time points, we identified preliminary candidate response prediction biomarkers that warrant further validation in a larger cohort of patient-derived tumor models and through confirmatory functional studies.
- Published
- 2012
- Full Text
- View/download PDF